Ainos, Inc. (AIMD) Stock

Ainos, Inc., a healthcare innovator, specializes in developing cutting-edge medical technologies aimed at enhancing point-of-care testing and advancing safe and novel medical treatments for various disease indications. The company's diverse product portfolio includes the COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a comprehensive platform integrating rapid antigen testing with personalized and enterprise-level applications. Additionally, Ainos offers COVID-19 nucleic acid tests and point-of-care testing for volatile organic compounds, addressing critical needs in diagnostic healthcare.

Ainos is also pioneering the development of Very Low-Dose Oral Interferon Alpha, a unique formulation known for its broad therapeutic applications. This innovative approach leverages interferon-alpha's potential in treating a wide range of conditions. Moreover, the company is actively engaged in advancing Synthetic RNA technology through its SRNA platform, contributing to advancements in molecular diagnogstics and therapeutic development, particularly in Taiwan.

Founded in 1984 and headquartered in San Diego, California, Ainos, Inc. (formerly known as Amarillo Biosciences, Inc.) has evolved to forefront medical technology innovation. With a steadfast commitment to improving healthcare outcomes through groundbreaking solutions, Ainos continues to push the boundaries of medical science, positioning itself as a key player in the global healthcare landscape.